WallStreetZen

NASDAQ: NURO
NeuroMetrix Inc Stock

$14.90-1.14 (-7.11%)
Updated Jul 30, 2021
NURO Price
$14.90
Fair Value Price
N/A
Market Cap
$83.87M
52 Week Low
$1.39
52 Week High
$38.75
P/E
-55.19x
P/B
9.49x
P/S
1.58x
PEG
N/A
Dividend Yield
N/A
Revenue
$8.21M
Earnings
-$1.17M
Gross Margin
73.9%
Operating Margin
-14.29%
Profit Margin
-14.3%
Debt to Equity
0.22
Operating Cash Flow
-$804k
Beta
0.86
Next Earnings
N/A
Ex-Dividend
N/A
Next Dividend
N/A

NURO Overview

Zen Score

High
Medium
Low
24
Industry average

Reasons for this score

NURO is poor value based on its book value relative to its share price (9.49x), compared to the US Medical Instruments & Supplies industry average (4.96x)
Valuation
NURO's cash and short-term investments ($8.36M) can cover NURO's cash burn for the next year ($876.61k), even accounting for increasing cash burn (89.52%)
Financials
NURO's profit margin has increased (+39.9%) in the last year from (-54.2%) to (-14.3%), and is approaching profitability
Financials

1 of 5

NURO News

Valuation

NURO fair value

Fair Value of NURO stock based on Discounted Cash Flow (DCF)
Price
$14.90
Fair Value
$19.68
Undervalued by
24.30%

NURO price to earnings (PE)

For valuing profitable companies with steady earnings
Company
-55.19x
Industry
-62.61x
Market
31.55x

NURO price to book (PB)

For valuing companies that are loss-making or have lots of physical asset
Company
9.49x
Industry
4.96x
NURO is poor value based on its book value relative to its share price (9.49x), compared to the US Medical Instruments & Supplies industry average (4.96x)
Valuation

NURO's financial health

Profit margin

Revenue
$2.2M
Net Income
-$531.6k
Profit Margin
-24%
NURO's cash and short-term investments ($8.36M) can cover NURO's cash burn for the next year ($876.61k), even accounting for increasing cash burn (89.52%)
Financials
NURO's profit margin has increased (+39.9%) in the last year from (-54.2%) to (-14.3%), and is approaching profitability
Financials

Assets to liabilities

Assets
$10.8M
Liabilities
$1.9M
Debt to equity
0.09
NURO's short-term assets ($10.03M) exceed its short-term liabilities ($1.58M)
Financials
NURO's short-term assets ($10.03M) exceed its long-term liabilities ($350.90k)
Financials
NURO's debt relative to shareholder equity (0.22) has decreased or remained constant compared to 5 years ago (0.26)
Financials
NURO's debt to equity ratio (0.22) is considered acceptable
Financials

Cash flow

Operating
-$534.9k
Investing
-$61.8k
Financing
$3.8M
NURO's cash and short-term investments ($8.36M) can cover NURO's cash burn ($876.61k) for at least 1 year
Financials

NeuroMetrix Stock FAQ

What is NeuroMetrix's quote symbol?

(NASDAQ: NURO) NeuroMetrix trades on the NASDAQ under the ticker symbol NURO. NeuroMetrix stock quotes can also be displayed as NASDAQ: NURO.

What is the 52 week high and low for NeuroMetrix (NASDAQ: NURO)?

(NASDAQ: NURO) NeuroMetrix's 52-week high was $38.75, and its 52-week low was $1.39. It is currently -61.55% from its 52-week high and 971.94% from its 52-week low.

How much is NeuroMetrix stock worth today?

(NASDAQ: NURO) NeuroMetrix currently has 5,628,907 outstanding shares. With NeuroMetrix stock trading at $14.90 per share, the total value of NeuroMetrix stock (market capitalization) is $83.87M.

NeuroMetrix stock was originally listed at a price of $92,736.00 in Jul 22, 2004. If you had invested in NeuroMetrix stock at $92,736.00, your return over the last 17 years would have been -99.98%, for an annualized return of -40.18%.

How much is NeuroMetrix's stock price per share?

(NASDAQ: NURO) NeuroMetrix stock price per share is $14.90 today (as of Jul 30, 2021).

What is NeuroMetrix's Market Cap?

(NASDAQ: NURO) NeuroMetrix's market cap is $83.87M, as of Aug 1, 2021.

Market cap (market capitalization) is the total market value of a publicly traded company's outstanding shares.

NeuroMetrix's market cap is calculated by multiplying NURO's current stock price of $14.90 by NURO's total outstanding shares of 5,628,907.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.

Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.